Evidence map›Paper›PMID 28134564›Full record

ArticleDiabetes technology & therapeutics2017

Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes.

Satish K Garg, Stuart A Weinzimer, William V Tamborlane, Bruce A Buckingham, Bruce W Bode, Timothy S Bailey, Ronald L Brazg, Jacob Ilany, Robert H Slover, Stacey M Anderson and 7 more

4 registry-linked trialsOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes technology & therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 245 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
245citing papers in PubMed, 9 pooled it
51.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02463097 nacompletednot on this map

Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes

TypeinterventionalSponsorMedtronic MiniMed, Inc.Ran2015 to 2018Enrolled124ConditionsType 1 DiabetesArmsInsulin Pump
NCT04509362 completednot on this mapstarted 2020, after this paper: background citation

An 8-Day Initiation Protocol of Advanced Hybrid Closed Loop System In Children and Adolescents With Diabetes Type 1 On Multiple Daily Insulin Injection

TypeobservationalSponsorSidra MedicineRan2020 to 2021Enrolled34ConditionsType 1 DiabetesArmsAdvanced Hybrid Closed Loop System
NCT05477030 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Effect of Automated Insulin Delivery With Advanced Closed-loop on Glucose Outcomes and Early-stage Diabetic Complications

TypeinterventionalSponsorUniversity of MilanRan2022 to 2024Enrolled52ConditionsType 1 DiabetesArmsMedtronic MiniMed 780G with SmartGuard activation, Medtronic MiniMed 780G without SmartGuard activation
NCT06115460 phase3completednot on this mapstarted 2022, after this paper: background citation

The Impact of Sitagliptin as an Add on Therapy With Closed Loop Control in Adolescents With Type 1 Diabetes Mellitus and Diabetic Nephropathy

TypeinterventionalSponsorAin Shams UniversityRan2022 to 2023Enrolled46ConditionsType 1 Diabetic NephropathyArmsoral sitagliptin supplementation
3 · Its place in the literature

Who cites it

245 citing papers in PubMed, 9 syntheses or guidelines pooled it, 569 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Real-World Evidence of Automated Insulin Delivery System Use.Diabetes technology & therapeutics · 2024
    Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022
    Guideline
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

185 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 2 countries.

Satish K Garg1 Barbara Davis Center for Diabetes, University of Colorado Denver , Aurora, Colorado.
Stuart A Weinzimer2 Yale University , New Haven, Connecticut.
William V Tamborlane2 Yale University , New Haven, Connecticut.
Bruce A Buckingham3 Stanford University , Stanford, California.
Bruce W Bode4 Atlanta Diabetes Associates , Atlanta, Georgia .
Timothy S Bailey5 AMCR Institute , Escondido, California.
Ronald L Brazg6 Rainier Clinical Research Center , Renton, Washington.
Jacob Ilany7 Sheba Medical Center , Tel Hashomer, Israel .
Robert H Slover1 Barbara Davis Center for Diabetes, University of Colorado Denver , Aurora, Colorado.
Stacey M Anderson8 University of Virginia , Charlottesville, Virginia.
Richard M Bergenstal9 International Diabetes Center , Minneapolis, Minnesota.
Benyamin Grosman10 Medtronic , Northridge, California.
Anirban Roy10 Medtronic , Northridge, California.
Toni L Cordero10 Medtronic , Northridge, California.
John Shin10 Medtronic , Northridge, California.
Scott W Lee10 Medtronic , Northridge, California.
Francine R Kaufman10 Medtronic , Northridge, California.
Medtronic (United States) · USUniversity of Colorado Denver · USYale University · USAMCR Institute · USAtlanta Diabetes Associates · USRainier Clinical Research Center · USSheba Medical Center · ILStanford University · USUniversity of Virginia · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe safety and effectiveness of the in-home use of a hybrid closed-loop (HCL) system that automatically increases, decreases, and suspends insulin delivery in response to continuous glucose monitoring were investigated.

methodsAdolescents (n = 30, ages 14-21 years) and adults (n = 94, ages 22-75 years) with type 1 diabetes participated in a multicenter (nine sites in the United States, one site in Israel) pivotal trial. The Medtronic MiniMed

resultsAdolescents (mean ± standard deviation [SD] 16.5 ± 2.29 years of age and 7.7 ± 4.15 years of diabetes) used the system for a median 75.8% (interquartile range [IQR] 68.0%-88.4%) of the time (2977 patient-days). Adults (mean ± SD 44.6 ± 12.79 years of age and 26.4 ± 12.43 years of diabetes) used the system for a median 88.0% (IQR 77.6%-92.7%) of the time (9412 patient-days). From baseline run-in to the end of study phase, adolescent and adult HbA

conclusionsHCL therapy was safe during in-home use by adolescents and adults and the study phase demonstrated increased time in target, and reductions in HbA

trial registrationClinicaltrials.gov identifier: NCT02463097.

Indexed as

Insulin Infusion SystemsAdolescentAdultAgedBlood GlucoseDiabetes Mellitus, Type 1FemaleGlycated HemoglobinHumansHypoglycemic AgentsInsulinMaleMiddle AgedTreatment OutcomeYoung AdultBlood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulinContinuous glucose monitoringHybrid closed loopHyperglycemiaHypoglycemiaInsulin pumpSensorType 1 diabetes

Identifiers

PMID28134564
PMCPMC5359676
OpenAlexW2587843318

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.